An observational study in Acute Hypoxemic Respiratory Failure and Noninvasive Ventilation, sponsored by Ruijin Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Ruijin Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Respiratory Insufficiency with a site in China — 30 open to participants now, 30 under way, 1 of them phase 3. Respiratory Insufficiency · China.
Among the 93 studies in Respiratory Insufficiency with a site in China, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 7 that started in 2026, is one of 36 observational ones, reaches primary completion later than 26 of the 29 other live ones, and was the 93rd registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 265 are open to participants now.
Browse Respiratory Insufficiency studies →30 of the 93 studies in Respiratory Insufficiency with a site in China are open now. Recruiting first, the newest first:
Zhongda Hospital · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18+
Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 4
First in 2007; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 100 across 455 observational studies indexed under Respiratory Insufficiency.
Median enrollment 120 across the 57 interventional studies, 175 across the 36 observational. Of the 36 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 93 has an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Ruijin Hospital has 5 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07051980Zhejiang UniversityFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study | 2026-12-02 |
| NCT07372794Capital Medical UniversityEIT-Guided Respiratory Physiotherapy for Prolonged Mechanical Ventilation (PMV) | 2026-12-14 |
| NCT07307066Peking Union Medical College HospitalReal-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study) | 2026-12-30 |
| NCT07366541Ruijin HospitalPredicting High-Flow Nasal Oxygen Failure Within 72 Hours Using a Physiology-Informed Dual-Domain Model at 30 Minutes | 2026-12-31 |
| NCT07898319Ruijin HospitalDevelopment and Prospective Validation of the AutoEIT Foundation Model for ARDS | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 93 studies in Respiratory Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter prospective observational cohort study with a nested physiological substudy. It aims to enroll 220 adults with acute hypoxemic respiratory failure (AHRF) initiating mask noninvasive ventilation (NIV). The study will assess the measurement feasibility, physiological associations, and early prognostic discrimination of the electrical impedance tomography (EIT)-derived flow index (EFI) during NIV. The primary objective is to estimate how well pre-landmark T1 EFI discriminates the risk of endotracheal intubation or all-cause death through 48 hours. A nested physiological substudy (n=20) will evaluate the within-patient association between EFI and airway occlusion pressure across fixed pressure support (PS) levels (5, 10, and 15 cmH2O). Clinical management remains independent of study measurements.
This study will enroll adults with AHRF for whom the treating team has decided to initiate mask NIV. The main cohort (n=220) is observational. EIT data will be acquired at baseline (T0), 60-120 min (T1), 20-24 h (T2), and 42-48 h (T3). The primary predictor is the median EFI across valid breaths during T1 (before the 2-h landmark). The primary endpoint is the first occurrence of endotracheal intubation or all-cause death after 2 h and through 48 h among patients eligible at the 2-h landmark.
A nested, non-randomized physiological substudy (n=20) will be conducted after T1. After confirming safety and obtaining separate informed consent, patients will undergo a fixed sequence of brief pressure support steps (PS 5, 10, and 15 cmH2O) with EPAP and FiO2 held at clinical settings. Brief airway occlusions will be performed at each level to measure occlusion pressure (Pocc and P0.1). The substudy aims to estimate the within-patient association between EFI and \|Pocc\|. The study was approved by the Ethics Committee of Ruijin Hospital (Approval No. 2026846). Written informed consent is obtained from all participants (and separate consent for the substudy).
Adults (aged 18 years or older) with acute hypoxemic respiratory failure (AHRF) for whom the treating clinical team has decided to initiate mask noninvasive ventilation (NIV) in the intensive care unit. A subset of stable patients will participate in the nested physiological sub-study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with AHRF initiating mask NIV (n=220). Observational; T1 EFI is evaluated for discriminating 48-hour intubation or death.
Other: Noninvasive Ventilation (NIV) · Device: Electrical Impedance Tomography (EIT) Monitoring
A subset of the main cohort (n=20). Consenting patients undergo brief, sequential pressure support (PS) adjustments (5, 10, 15 cmH2O) and airway occlusions to measure EFI and \|Pocc\| associations.
Other: Noninvasive Ventilation (NIV) · Device: Electrical Impedance Tomography (EIT) Monitoring · Other: Brief Pressure Support Adjustment and Airway Occlusion (Substudy only)
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team.
Continuous EIT monitoring to derive the dimensionless flow index (EFI).
Protocol-specified PS steps (5, 10, 15 cmH2O) and device-supported airway occlusions performed in the physiological substudy.
Incidence of Endotracheal Intubation or All-Cause Death (2h to 48h)
The first occurrence of endotracheal intubation or all-cause death after 2 hours and through 48 hours from NIV initiation, among patients alive and still receiving NIV at the 2-hour landmark.Unit of Measure: Proportion of participants (or Event count)
Time frame: After 2 hours through 48 hours.
Discrimination Performance (AUC) of T1 EFI
Area under the receiver operating characteristic curve (AUC) of the pre-landmark T1 EFI for predicting the primary composite endpoint.Unit of Measure: AUC (dimensionless, 0-1)
Time frame: Within 72 hours
Within-Patient Association between EFI and |Pocc|
The within-patient slope of the association between EFI and the absolute magnitude of occlusion pressure (\|Pocc\|) across fixed pressure support levels in the physiological sub-study. Unit of Measure: cmH2O per unit of EFI
Time frame: Within 2 to 6 hours after NIV initiation.
Intubation or Death by Day 7
ncidence of endotracheal intubation or all-cause mortality by day 7.Unit of Measure: Proportion of participants
Time frame: Within day 7
28-Day All-Cause Mortality
All-cause mortality rate at day 28.Unit of Measure: Proportion of participants
Time frame: within day 28
Plan to share: Undecided — De-identified analysis datasets may be shared on reasonable request for verification, subject to ethics approval.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.
Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 21 months is close to that.
Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.